Lexington, MA, United States of America

Emmanuelle Di Tomaso

USPTO Granted Patents = 3 

 

 

Average Co-Inventor Count = 4.3

ph-index = 1


Company Filing History:


Years Active: 2017-2019

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Emmanuelle Di Tomaso: Innovator in Pharmaceutical Science

Introduction

Emmanuelle Di Tomaso is a notable inventor based in Lexington, MA (US). He has made significant contributions to the field of pharmaceutical science, particularly in the development of innovative treatments for proliferative diseases and cancers.

Latest Patents

Di Tomaso holds 3 patents, with his latest inventions focusing on advanced therapeutic methods. One of his notable patents is a dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. This invention relates to methods of treating or preventing a proliferative disease by orally administering a therapeutically effective amount of the inhibitor compound for specific cycles. Another significant patent involves a combination of a PI3 kinase inhibitor with paclitaxel for the treatment or prevention of head and neck cancers. This pharmaceutical combination aims to enhance the effectiveness of cancer treatment through a synergistic approach.

Career Highlights

Emmanuelle Di Tomaso is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on groundbreaking research and development in the pharmaceutical sector.

Collaborations

Di Tomaso has collaborated with esteemed colleagues, including Cristian Massacesi and Christine Fritsch, who contribute to the innovative environment at Novartis.

Conclusion

Emmanuelle Di Tomaso's contributions to pharmaceutical science through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in the treatment of serious health conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…